Pharma BD Deal Intelligence
Alnylam CEO John Maraganore: 'This new relationship with Genzyme is transformational for Alnylam. It is a game changer for both the advancement of RNAi…
PharmaTimes reports Sanofi/Genzyme spent $700 million for an approximately 12% stake in Alnylam, summarizing the expanded RNAi rare-disease collaboration…
Retrospective noting Sanofi and Alnylam concluded the research phase of their RNAi alliance, reviewing how the 2014 collaboration evolved over its term.
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Sanofi's Genzyme unit paid Alnylam approximately $700M for a 12% equity stake plus expanded ex-U.S. rights to Alnylam's RNAi rare-disease pipeline including patisiran. The deal anchored Sanofi's bet on RNAi as a platform and was one of the largest equity-plus-rights packages of 2014.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Alnylam Pharmaceuticals Inc. (this deal) | 2014 | $700M | 36 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2014 deals · Sanofi SA deals · Cardiovascular deals